South and Southeast Asia sit at the epicentre of a global oral cancer crisis. According to a 2024 Lancet Oncology analysis, more than 120,000 cases of oral cancer annually — roughly 30% of the global total — are attributable to smokeless tobacco use, areca nut consumption, or both. Of those cases, 87.8% occur in south-central Asia. This is not a marginal public health problem; it is one of the most concentrated preventable cancer burdens on earth.
A January 2026 review published in Frontiers in Oral Health — authored by researchers across institutions including the University of Birmingham — examined this epidemiological landscape and asked a pointed question: in a region where traditional smokeless tobacco products cause devastating harm, could modern tobacco-free nicotine pouches serve as a harm-reduction pathway?
Why the Region’s Tobacco Problem Is Different
The oral cancer burden in South and Southeast Asia is not driven by cigarettes. It is driven by an array of culturally embedded, often artisanally produced smokeless tobacco products — gutka, khaini, toombak, betel quid with tobacco — many of which contain extremely high levels of tobacco-specific nitrosamines (TSNAs), the primary carcinogenic driver.
India and Bangladesh together account for roughly 80% of global smokeless tobacco users. In India, smokeless tobacco represents 61% of total tobacco consumption — and the product landscape includes more than 400 distinct commercial brands, supplemented by street-vendor-assembled preparations that vary wildly in carcinogen content. In several countries in the region, prevalence of smokeless tobacco use among youth rivals or exceeds cigarette smoking rates.
Areca nut — a Group 1 carcinogen in its own right, widely used across South Asia, Southeast Asia, and the Pacific — amplifies the problem independently of tobacco. Many regional products combine areca nut with tobacco, stacking carcinogenic exposures in ways that Western tobacco harm-reduction frameworks were never designed to address.
What Modern Nicotine Pouches Are — and Aren’t
Modern oral nicotine pouches — the white, spit-free, tobacco-leaf-free products sold as Zyn, Velo, On!, and dozens of regional equivalents — are a categorically different product from the smokeless tobacco driving oral cancer in Asia. Toxicological analyses reviewed in the Frontiers paper show that authorized nicotine pouches contain significantly lower levels of TSNAs and other harmful constituents than both cigarettes and traditional smokeless tobacco products.
Short-term clinical studies included in the review found reductions in oral mucosal irritation and gingival inflammation among exclusive pouch users compared to smokers or smokeless tobacco users. The researchers note that “nicotine itself does not cause cancer” — the carcinogenic burden of tobacco products comes primarily from combustion byproducts and TSNAs, not from nicotine.
The critical caveat: long-term data on nicotine pouch-specific oral cancer risk does not yet exist. The products are too new. A 2024 systematic review covering the oral health literature through February 2024 found only three human studies meeting inclusion criteria — and all three had high risk of bias. The evidence base is thin.
The Harm Reduction Calculus
For Western markets, the harm reduction argument for nicotine pouches is primarily about cigarette substitution — a well-documented risk hierarchy in which combustion is the primary danger. The FDA authorized flavoured Zyn products in January 2025 on exactly this basis: that for adults who smoke, the benefits of switching outweigh the residual risks of pouch use.
In South and Southeast Asia, the argument would have to work differently. The relevant comparator isn’t the cigarette — it’s the gutka pouch or the khaini wad, products with carcinogen loads that dwarf anything in the authorized nicotine pouch category. If a chronic gutka user switched entirely to a modern nicotine pouch, the toxicological improvement would be dramatic. The TSNA exposure alone would drop by orders of magnitude.
But the real-world dynamics are complex. Cultural attachment to traditional products is deep. Price points matter — modern nicotine pouches are premium products globally. And regulatory frameworks across the region are inconsistent: Thailand maintains one of the strictest nicotine regimes in Asia, while Vietnam’s regulatory status for pouches is still under review. Indonesia has limited guidance specifically addressing modern oral pouches. Malaysia regulates them as pharmaceuticals.
What the Research Calls For
The Frontiers review stops well short of recommending nicotine pouches as a public health intervention in Asia. The authors call for longitudinal studies specifically tracking oral mucosal changes in exclusive pouch users, direct comparisons with traditional smokeless tobacco users in high-burden populations, and regulatory frameworks that distinguish modern nicotine pouches from the traditional smokeless tobacco driving cancer burden.
The New England Journal of Medicine published a complementary perspective in January 2026 that underscored the research gap: despite 360 million smokeless tobacco users globally and rising oral cancer incidence, policy and research have lagged dramatically behind the cigarette-focused public health establishment.
The question of whether modern nicotine pouches can reduce harm in South and Southeast Asia is genuinely open — and genuinely important. Getting the answer right, with rigorous evidence rather than ideology in either direction, could matter for millions of people whose oral cancer risk is driven by products that modern nicotine pouches are nothing like.
